ProMIS Neurosciences Inc. (PMN) Form 8-K — Aug 13, 2026
ProMIS Neurosciences reported a Q2 2026 net loss of $11.7 million, or $1.28 per share, versus a $10.1 million loss, or $7.26 per share, in the year-ago quarter. The per-share improvement reflects a much larger share count following the January 2026 financing, while quarterly R&D spend rose to $9.5 million from $8.7 million. The company ended the quarter with $53.4 million in cash and short-term investments, up from $6.1 million at December 31, 2025, driven by $70.1 million in net private placement proceeds received in January 2026. Management expects these resources to fund operations through 2027, beyond the anticipated 12-month topline PRECISE-AD readout in Q1 2027.
Key figures
- Guidance
- Cash and short-term investments of $53.4 million expected to fund operations through 2027, beyond the anticipated 12-month topline PRECISE-AD readout expected in Q1 2027.
- Total Assets
- 56693933
- Cash Position
- 53429280
- Aria ECases
- 0
- Trial Sites
- 22
- Cash Dec31 2025
- 6116556
- Enrolled Subjects
- 144
- Ga Expense Q2 2026
- 2744606
- Rd Expense Q2 2026
- 9521793
- Prior Year Q2 Net Loss
- 10117029
- Total Aria Incidence
- 4.4% (all mild ARIA-H, asymptomatic)
- Six Month Net Loss2026
- 19974029
- Csf MTBRTau243 Decline
- ~13.3%, with ~62.5% of patients declining
- Plasma PTau217 Decline
- ~15% from baseline through Day 169, with ~68.5% of patients declining
- Topline Readout Expected
- Q1 2027 (unblinded 12-month data with cognitive outcomes)
- Weighted Avg Shares Q2 2026
- 9142366
- Total Operating Expenses Q2 2026
- 12266399
- Interim Safety Evaluable Participants
- 136
- Private Placement Net Proceeds Jan2026
- 70100000
Price after filing
Close on the filing date to close N calendar days later (from $14.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.